Dapsone

Dermatologic Therapy

Volumn 15, Issue 4, 2002, Pages 340-351

  Sago, Joni ^a   Hall, Russell P ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Dapsone; Dermatitis herpetiformis; Linear IgA disease

Indexed keywords

ALPHA TOCOPHEROL; ANTIMALARIAL AGENT; CHEMOATTRACTANT; DAPSONE; HYDROXYCHLOROQUINE; METHYLENE BLUE; PROBENECID; RIFAMPICIN; SULFAPYRIDINE; SULFONAMIDE;

AGRANULOCYTOSIS; BINDING SITE; BLISTER; BULLOUS SKIN DISEASE; CANCER RISK; CELL INFILTRATION; CHEMICAL BINDING; CHEMOTAXIS; CHOLESTATIC HEPATITIS; DERMATITIS HERPETIFORMIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; EOSINOPHILIA; ERYTHEMA MULTIFORME; FEVER; GASTROINTESTINAL TOXICITY; HEADACHE; HEMOLYTIC ANEMIA; HEPATITIS; HUMAN; HYPOALBUMINEMIA; IMMUNOGLOBULIN A DEFICIENCY; INFLAMMATION; LEUKOCYTOSIS; LYMPHOCYTOSIS; METHEMOGLOBINEMIA; MOTOR NEUROPATHY; NEPHROTOXICITY; NERVOUSNESS; NEUROPATHY; NEUTROPHIL; OPTIC NERVE ATROPHY; PATIENT MONITORING; PATIENT SELECTION; PHARYNGITIS; PHOTOSENSITIVITY; PRACTICE GUIDELINE; PREGNANCY COMPLICATION; RASH; REVIEW; SEPSIS; SKIN DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; TOXIC EPIDERMAL NECROLYSIS;

EID: 0036966716     PISSN: 13960296     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1529-8019.2002.01543.x     Document Type: Review

References (98)

1. Costello MJ. Sulfapyridine in the treatment of dermatitis herpetiformis. Arch Dermatol Syph 1947: 56: 614-622.
2. Esteves J, Brando FN. Au sujet de Faction des sulfamides et des sulphones dans la maladie de Dhuring. Trans Soc Port Dermatol 1950: 8: 209-211.
3. Kruizinga EE, Hamminga H. Treatment of dermatitis herpetiformis with diaminodiphenylsulphone (DDS). Dermatologica 1953: 106: 386-394.
4. Leonard JN, Fry L. Treatment and management of dermatitis herpetiformis. Clin Dermatol 1991: 9: 403-408.
5. Battle GAH. Treatment of streptococcal infections in mice with 4,4′ diaminodiphenylsulfone. Lancet 1937: 1331-1334.
6. Feldman WH, Henshaw HC, Moses HE. Treatment of experimental tuberculosis with Promin (sodium salt P, P′-diamino-diphenyl sulfone N, N′ dextrose sulfonates): preliminary report. Proc Staff Meet Mayo Clin 1941: 18: 118-125.
7. Uetrecht JP. Dapsone and sulfapyridine. Clin Dermatol 1989: 7: 111-120.
8. Zuidema J, Hilbers-Modderman ESM, Merkus FWHM. Clinical pharmacokinetics of dapsone. Clin Pharmacokinet 1986: 11: 299-315.
9. Mancey-Jones B. The mode of action of dapsone in leprosy and other disorders. In: Ryan TJ, McDougall AC, eds. Essay on Leprosy. Oxford: Alden Press, 1988: 141-172.
10. Swain AF, Ahmad RA, Rogers HJ, Leonard J, Fry L. Pharmacokinetic observation on dapsone in dermatitis herpetiformis. Br J Dermatol 1983: 108: 91-98.
11. Wright JT, Das AK. The absorption of dapsone by patients with dermatitis herpetiformis and coeliac disease. Clin Exp Dermatol 1980: 5: 27-30.
12. Sanders SW, Zone JJ. The relationship between dapsone dose, serum concentration and disease severity in dermatitis herpetiformis. Arzneimittelforschung 1986: 36: 146-149.
13. Sanders SW, Zone JJ, Foltz RL, Tolman KG, Rollins DE. Hemolytic anemia induced by dapsone transmitted through breast milk. Ann Intern Med 1982: 96: 465-466.
14. Maurus JN. Hansen's disease in pregnancy. Obstet Gynecol 1978: 52: 22-25.
15. Gill HJ, Tingle MD, Park BK. N-hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity. Br J Clin Pharmacol 1995: 40: 531-538.
16. Jollow DJ, Bradshaw TP, McMillan DC. Dapsone-induced hemolytic anemia [review]. Drug Metab Rev 1995: 27: 107-124.
17. Cucinell SA, Israili ZH, Dayton PG. Microsomal N-oxidation of dapsone as a cause of methemoglobin formation in human red cells. Am J Trop Med Hyg 1972: 21: 322-331.
18. Coleman MD, Scott AK, Breckenridge AM, Park BK. The use of cimetidine as a selective inhibitor of dapsone N-hydroxylation in man. Br J Clin Pharmacol 1990: 30: 761-767.
19. Coleman MD, Rhodes LE, Scott AK, et al. The use of cimetidine to reduce dapsone-dependent methaemoglobinaemia in dermatitis herpetiformis patients. Br J Clin Pharmacol 1992: 34: 244-249.
20. May DG, Arns PA, Richards WO, et al. The disposition of dapsone in cirrhosis. Clin Pharmacol Ther 1992: 51: 689-700.
21. Schmidt E, Reimer S, Kruse N, Brocker EB, Zillikens D. The IL-8 release from human keratinocytes, mediated by antibodies to bullous pemphigoid autoantigen 180, is inhibited by dapsone. Clin Exp Immunol 2001: 124: 157-162.
22. Wozel G, Lehmann B. Dapsone inhibits the generation of 5-lipoxygenase products in human polymorphonuclear leukocytes. Skin Pharmacol 1995: 8: 196-202.
23. Maloff BL, Fox D, Bruin E, Di MT. Dapsone inhibits LTB4 binding and bioresponse at the cellular and physiologic levels. Eur J Pharmacol 1988: 158: 85-89.
24. Stendahl O, Dahlgren C. The inhibition of polymorphonuclear leukocyte cytotoxicity by dapsone: a possible mechanism in the treatment of dermatitis herpetiformis. J Clin Invest 1977: 62: 214-220.
25. Esterly NB, Furey NL, Flanagan LE. The effect of antimicrobial agents on leukocyte chemotaxis. J Invest Dermatol 1978: 70: 51-55.
26. Millar BW, Macdonald KJ, Macleod TM, Raffle EJ. Dapsone and human polymorphonuclear leucocyte chemotaxis in dermatitis herpetiformis. Acta Derm Venereol 1984: 64: 433-436.
27. Harvath L, Yancey KB, Katz SI. Selective inhibition of human neutrophil chemotaxis to N-formyl-methionylleucyl-phenylalanine by sulfones. J Immunol 1986: 137: 1305-1311.
28. Thuong-Nguyen V, Kadunce DP, Hendrix JD, Gammon WR, Zone JJ. Inhibition of neutrophil adherence to antibody by dapsone: a possible therapeutic mechanism of dapsone in the treatment of IgA dermatoses. J Invest Dermatol 1993: 100: 349-355.
29. Booth SA, Moody CE, Dahl MV, Herron MJ, Nelson RD. Dapsone suppresses integrin-mediated neutrophil adherence function. J Invest Dermatol 1992: 98: 135-140.
30. Debol SM, Herron MJ, Nelson RD. Anti-inflammatory action of dapsone: inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transduction. J Leukoc Biol 1997: 62: 827-836.
31. Modschiedler K, Weller M, Worl P, Von den Driesch, P. Dapsone and colchicine inhibit adhesion of neutrophilic granulocytes to epidermal sections. Arch Dermatol Res 2000: 292: 32-36.
32. Bozeman PM, Learn DB, Thomas EL. Inhibition of the human leukocyte enzymes myeloperoxidase and eosinophil peroxidase by dapsone. Biochem Pharmacol 1992: 44: 553-563.
33. Fry L. The treatment of dermatitis herpetiformis. Clin Exp Dermatol 1982: 7: 633-642.
34. Katz SI. Treatment: drugs and diet. In: Katz SI (moderator). Dermatitis herpetiformis: the skin and the gut. Ann Intern Med 1980: 93: 857-874.
35. Leonard JN, Haffenden GP, Ring NP, et al. Linear IgA disease in adults. Br J Dermatol 1982: 107: 301-316.
36. Chorzelski TP, Jablonska S. IgA linear dermatosis of childhood (chronic bullous disease of childhood). Br J Dermatol 1979: 101: 535-542.
37. Wojnarowska F, Marsden RA, Bhogal B, Black MM. Chronic bullous disease of childhood, childhood cicatricial pemphigoid and linear IgA disease of adults; A comparative study demonstrating clinical and immunopathologic overlap. J Am Acad Dermatol 1988: 19: 792-805.
38. Jablonska S, Chorzelski TP, Rosinska D, Maciejowska E. Linear IgA bullous dermatosis of childhood (chronic bullous dermatosis of childhood). Clin Dermatol 1992: 9: 393-401.
39. Hall RP, Lawley TJ, Smith HR, Katz SI. Bullous eruption of systemic lupus erythematosus. Dramatic response to dapsone therapy. Ann Intern Med 1982: 97: 165-170.
40. Basset N, Guillot B, Michel B, Meynadier J, Guilhou JJ. Dapsone as initial treatment in superficial pemphigus. Report of nine cases. Arch Dermatol 1987: 123: 783-785.
41. Rogers RS, Mehregan DA. Dapsone therapy of cicatricial pemphigoid. Semin Dermatol 1988: 7: 201-205.
42. Ciarrocca KN, Greenberg MS. A retrospective study of the management of oral mucous membrane pemphigoid with dapsone. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999: 88: 159-163.
43. Beutner EH, Chorzelski TP, Wilson RM, et al. IgA pemphigus foliaceus: report of two cases and a review of the literature. J Am Acad Dermatol 1989: 20: 89-97.
44. Bouscarat F, Chosidow O, Picard-Dahan C, et al. Treatment of bullous pemphigoid with dapsone: retrospective study of thirty-six cases. J Am Acad Dermatol 1996: 34: 683-684.
45. Bystryn JC. Adjuvant therapy of pemphigus. Arch Dermatol 1984: 120: 941-951.
46. Bystryn JC. Therapy of pemphigus. Semin Dermatol 1988: 7: 186-194.
47. Haim S, Friedman-Birnbaum R. Dapsone in the treatment of pemphigus vulgaris. Dermatologica 1978: 156: 120-123.
48. Honeyman JF, Honeyman AR, De la Parra MA, Pinto A, Eguiguren GJ. Polymorphic pemphigoid. Arch Dermatol 1979: 115: 423-427.
49. Jeffes EWB III, Ahmed AR. Adjuvant therapy of bullous pemphigoid with dapsone. Clin Exp Dermatol 1989: 14: 132-136.
50. Person JR, Rogers RS. Bullous pemphigoid responding to sulfapyridine and the sulfones. Arch Dermatol 1977: 113: 610-615.
51. Rogers RS, Seehafer JR, Perry HO. Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone. J Am Acad Dermatol 1982: 6: 215-223.
52. Tauber J, Sainz de la Maza M, Foster CS. Systemic chemotherapy for ocular cicatricial pemphigoid. Cornea 1991: 10: 185-195.
53. Terezhalmy GT, Bergfeld WF. Cicatricial pemphigoid (benign mucous membrane pemphigoid). Quintessence Int 1998: 29: 429-437.
54. Venning VA, Millard PR, Wojnarowska F. Dapsone as first line therapy for bullous pemphigoid. Br J Dermatol 1989: 120: 83-92.
55. Elder MJ, Leonard J, Dart JK. Sulphapyridine - a new agent for the treatment of ocular cicatricial pemphigoid. Br J Ophthalmol 1996; 80: 549-552.
56. Doan S, Lerouic JF, Robin H, et al. Treatment of ocular cicatricial pemphigoid with sulfasalazine. Ophthalmology 2001: 108: 1565-1568.
57. Yasuda H, Kobayashi H, Hashimoto T, et al. Subcorneal pustular dermatosis type of IgA pemphigus: demonstration of autoantibodies to desmocollin-1 and clinical review. Br J Dermatol 2000: 143: 144-148.
58. Ongenae KC, Temmerman LJ, Vermander F, Naeyaert JM. Intercellular IgA dermatosis. Eur J Dermatol 1999: 9: 85-94.
59. Beumont MG, Graziani A, Ubel PA, MacGregor RR. Safety of dapsone as Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with allergy to trimethoprim/sulfamethoxazole. Am J Med 1996: 100: 611-616.
60. Holtzer CD, Flaherty JFJ, Coleman RL. Cross-reactivity in HIV-infected patients switched from trimethoprimsulfamethoxazole to dapsone. Pharmacotherapy 1998: 18: 831-835.
61. Hjelm M, DeVerdier C-H. Biochemical effects of aromatic amines-I Methaemoglobinaemia, haemolysis and Heinz-body formation induced by 4,4′-diaminodiphenylsulphone. Biochem Pharmacol 1965: 14: 1119-1128.
62. Coleman MD. Dapsone toxicity: some current perspectives. Gen Pharmacol 1995: 26: 1461-1467.
63. Motulsky AG, Yoshida A, Stametoyannopoulos G. Variants of glucose-6-phosphate dehydrogenase. Ann N Y Acad Sci 1971: 179: 636-643.
64. Eichelbaum M, Evert B. Influence of pharmacogenetics on drug disposition and response. Clin Exp Pharmacol Physiol 1996: 23: 983-985.
65. Coleman MD. Dapsone: modes of action, toxicity and possible strategies for increasing patient tolerance. Br J Dermatol 1993: 129: 507-513.
66. Prussick R, Ali MA, Rosenthal D, Guyatt G. The protective effect of vitamin E on the hemolysis associated with dapsone treatment in patients with dermatitis herpetiformis. Arch Dermatol 1992: 128: 210-213.
67. Rhodes LE, Tingle MD, Park BK, et al. Cimetidine improves the therapeutic/toxic ratio of dapsone in patients on chronic dapsone therapy. Br J Dermatol 1995: 132: 257-262.
68. Dawson AH, Whyte IM. Management of dapsone poisoning complicated by methaemoglobinaemia. Med Toxicol Adverse Drug Exp 1989: 4: 387-392.
69. Hornsten P, Keisu M, Wiholm B-E. The incidence of agranulocytosis during treatment of dermatitis herpetiformis with dapsone as reported in Sweden, 1972 through 1988. Arch Dermatol 1990: 126: 919-922.
70. Cockburn EM, Wood SM, Waller PC, Bleehen SS. Dapsone-induced agranulocytosis: spontaneous reporting data. Br J Dermatol 1993: 128: 702-703.
71. Coleman MD. Dapsone-mediated agranulocytosis: risks, possible mechanisms and prevention. Toxicology 2001: 162: 53-60.
72. Miyagawa S, Shiomi Y, Fukumoto T, Ishii Y, Shirai T. Recombinant granulocyte colony-stimulating factor for dapsone-induced agranulocytosis in leukocytoclastic vasculitis. J Am Acad Dermatol 1993: 28: 659-661.
73. Saqueton AC, Lorincz AL, Vick NA, Hamer RD. Dapsone and peripheral motor neuropathy. Arch Dermatol 1969: 100: 214-217.
74. Waldinger TP, Siegle RJ, Weber W, Voorhees JJ. Dapsone-induced peripheral neuropathy. Case report and review. Arch Dermatol 1984: 120: 356-359.
75. Koller WC, Gehlmann LK, Malkinson FD, Davis FA. Dapsone-induced peripheral neuropathy. Arch Neurol 1977: 34: 644-646.
76. Daneshmend TK. The neurotoxicity of dapsone. Adv Drug React Ac Pois Rev 1984: 3: 43-58.
77. Gutmann L, Martin JD, Welton W. Dapsone motor neuropathy - an axonal disease. Neurology 1976: 26: T-6.
78. Homeida M, Babikr A, Daneshmend TK. Dapsone-induced optic atrophy and motor neuropathy. BMJ 1980: 281: 1180.
79. Leonard JN, Tucker WF, Fry L, Marsh RJ, Ford S. Dapsone and the retina. Lancet 1982: 1: 453.
80. Daneshmend TK, Homeida M. Dapsone-induced optic atrophy and motor neuropathy. Br Med J 1981: 283: 311.
81. Daneshmend TK. Idiosyncratic dapsone induced manic depression. BMJ 1989: 299: 324.
82. Fine JD, Katz SI, Donahue MJ, Hendricks AA. Psychiatric reaction to dapsone and sulfapyridine. J Am Acad Dermatol 1983: 9: 274-275.
83. Gawkrodger D. Manic depression induced by dapsone in patient with dermatitis herpetiformis. Br Med J 1989: 299: 860.
84. Millikan LE, Harrell ER. Drug reactions to sulfones. Arch Dermatol 1970: 102: 220-224.
85. Johnson DA, Cattau EL Jr, Kuritsky JN. Liver involvement in the sulfone syndrome. Arch Intern Med 1986: 146: 875-877.
86. Corp CC, Ghishan FK. The sulfone syndrome complicated by pancreatitis and pleural effusion in an adolescent receiving dapsone for treatment of acne vulgaris. J Pediatr Gastroenterol Nutr 1998: 26: 103-105.
87. Kingham JGC, Swain P, Swarbrick ET, Walker JG, Dawson AM. Dapsone and severe hypoalbuminaemia. Lancet 1979: 2: 662-664.
88. Prussick R, Shear NH. Dapsone hypersensitivity syndrome. J Am Acad Dermatol 1996: 35: 346-349.
89. Frey HM, Gershon AA, Borkowsky W, Bullock WE. Fatal reaction to dapsone during treatment of leprosy. Ann Intern Med 1981: 94: 777-779.
90. Lawrence WA, Olsen HW, Nickles DJ. Dapsone hepatitis. Arch Intern Med 1987: 147: 175.
91. Gupta AK, Eggo MC, Uetrecht J. Pharmacodynamics and drug action. Drug-induced hypothyroidism: the thyroid as a target organ in hypersensitivity reactions to anticonvulsants and sulfonamides. Clin Pharmacol Ther 1992: 51: 56-67.
92. Reilly TP, Bellevue FH, Woster PM, Svensson CK. Comparison of the in vitro cytotoxicity of hydroxylamine metabolites of sulfamethoxazole and dapsone. Biochem Pharmacol 1998: 55: 803-810.
93. Kumar RH, Kumar MV, Thappa DM. Dapsone syndrome - a five year retrospective analysis. Indian J Lepr 1998: 70: 271-276.
94. Peters JH. Carcinogenic activity of dapsone. Int J Lepr 1976: 44: 383-384.
95. Collier PM, Kelly SE, Wojnarowska F. Linear IgA disease and pregnancy. J Am Acad Dermatol 1994: 30: 407-411.
96. Kahn G. Dapsone is safe during pregnancy. J Am Acad Dermatol 1985: 13: T-9.
97. Erturk E, Casemento JB, Guertin KR, Kende AS. Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy. J Urol 1994: 151: 1605-1606.
98. Todd P, Samaratunga IR, Pembroke A. Screening for glucose-6-phosphate dehydrogenase deficiency prior to dapsone therapy. Clin Exp Dermatol 1994: 19: 217-218.